GLP ‐1 Receptor Agonists Post‐Bariatric Surgery ( GRABS ) Trial: Rationale, Design and Baseline Characteristics
Authors' conclusion
GRABS is the first randomized trial to investigate GLP1RA effectiveness in patients with persistent obesity following RYGB
Study context
- Population
- Patients aged 25–65 with persistent obesity (BMI ≥ 30 kg/m²) enrolled 12 months after RYGB; excluded T1D, T2D treatment other than metformin, conversion to RYGB from prior bariatric surgery, GLP1RA use in past 3 months28 in final sample
- Participants
- 33 patients
- Comparison
- Tirzepatide (TRZ) with standard of care (SOC) vs SOC alone after RYGB
- Primary endpoint
- Total percent weight change from baseline
- Follow-up
- 24 weeks after trial initiation
Methodological detailsrationale, design and baseline characteristics, open-label, proof-of-concept, randomized 1:1
- Rationale, design and baseline characteristics
- Open-label
- Proof-of-concept
- Randomized 1:1
Primary result
As reported in the abstract
Baseline characteristics of final cohort
- Female
- 82%
- White
- 75%
- Median age
- 42.0 years
- Pre-surgery BMI
- 48.3 kg/m²
- Baseline BMI at randomization
- 36.0 kg/m²
- Baseline weight
- 95.6 kg
Original publication
GLP ‐1 Receptor Agonists Post‐Bariatric Surgery ( GRABS ) Trial: Rationale, Design and Baseline Characteristics. Diabetes Obes Metab. Published 8 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →